Singzyme’s mission is to deliver on the promise of effective immuno-therapies by developing more homogeneous and safer bioconjugates such as Antibody-Drug conjugates (ADCs) for the well-being of cancer patients worldwide. Backed by our first-in-class precision bioconjugation platform, we support global pharmaceutical industries with their Research and Development (R&D) endeavors to allow promising Biologics therapeutics to reach the patient’s bedside more rapidly. In addition, Singzyme has an in-house pipeline of ADCs and nanobody conjugates at various development phases.

VISIT WEBSITE